San Diego, CA -- (SBWIRE) -- 11/10/2006 -- SpectraScience, Inc. (SCIE.OB) announced today that it has filed for a new patent with the United States Patent and Trademark Office.
The application is titled “System and Method for Non-Endoscopic Optical Biopsy Detection of Diseased Tissue”. The device is a disposable catheter designed to be used in body cavities to detect normal or cancerous tissue. It is used in conjunction with the Company’s WavSTATTM Optical Biopsy System.
Jim Hitchin the Company’s CEO said, “our multi-patented and proprietary WavSTATTM Optical Biopsy System is used by physicians to diagnose tissue and determine if it is normal, pre-cancerous, or cancerous within one second. The WavStatTM System is currently approved by the FDA for use in detecting cancer in the colon. A new application for detecting pre-cancers in the throat, sometimes called Barrett’s esophagus, is being tested in a clinical trial. Cancer of the esophagus is more than 90% fatal and may develop as a result of chronic heartburn or GERD. Esophageal cancer is growing five times faster than all other cancers.”
This news release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from the results discussed in the forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, the Form 10-KSB and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
For further information contact Jim Hitchin at (858) 847-0200.